Parkinson's disease cognitive impairment
Conditions
Interventions
Acupuncture plus drug group (treatment group):The Four Divine Needles, Shenting, Yintang, Shenmen, and Sanyinjiao. After the needles are inserted into the above-mentioned acupoints to obtain qi, the n
Sham acupuncture plus drug group (Control group 1):The acupoint selection was the same as that of the acupuncture plus drug group. A blunt needle was used to apply the needle at a distance of 2 cm bes
Drug group (Control group 2):The patient took dopazid and donepezil to maintain the original effective therapeutic dose for the patient.
Sponsors
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
30 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Meet the diagnostic criteria for PD, and have been treated with dodopazid and donepezil for at least 3 months with stable doses, and the condition is in a stable phase. 2) Male or female, aged 30 to 80. 3) Total score of the Montreal Cognitive Scale (MoCA) is less than 25 points 4) The subjects were informed of the protocol and signed the informed consent form. 5) Patients with stable chronic diseases (such as hypertension, type 2 diabetes, etc.) are allowed to be enrolled, but their related treatment drugs (such as antihypertensive drugs, hypoglycemic drugs) must maintain a stable dose for at least 3 months before enrollment, and their conditions must be well controlled, and the drugs they are taking do not affect the assessment of this study.
Exclusion criteria
Exclusion criteria: 1) It is confirmed that there are serious diseases of other systems. 2) Identify other diseases that can lead to Parkinson's syndrome, such as Parkinson's syndrome, senile tremor, etc. 3) There is a definite presence of cerebellar ataxia or cerebellar eye movement abnormalities. 4) There is a clear loss of cortical complex sensation and apraxia or progressive aphasia of limb concepts and motor skills. 5) Downward vertical supranuclear gaze palsy or downward vertical sacroselective deceleration occurs. 6) Parkinson-like symptoms that remain confined to the lower extremities three years after the onset of the disease. 7) Diagnosed with highly suspected behavioral variant frontotemporal dementia or primary progressive aphasia within five years after the onset of the disease. 8) There was no significant therapeutic response to high-dose levodopa treatment. 9) Having participated in other clinical trials such as drugs and acupuncture within one month prior to being included in this study. 10) Those with a bleeding tendency or who are currently taking anticoagulant drugs. 11) Those with severe heart, liver or kidney insufficiency. 12) Those with a history of epilepsy or mental illness. 13) Pregnant or lactating women. 14) Those with local infection or damage to the scalp. 15) Patients with uncontrolled severe underlying diseases, or those accompanied by severe complications, other serious or unstable systemic diseases, and whose participation risk is judged by the researcher to be relatively high.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment;UPDRS-III scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serological testing: Amyloid Beta 42;Serological testing: Phosphorylated Tau at threonine 181;Serological testing: Glial Fibrillary Acidic Protein; | — |
Countries
China
Contacts
Public ContactYin Liwei
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Outcome results
None listed